Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Recruiting

Phase 2

RAP-219Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Sponsor:

Rapport Therapeutics Inc.

Code:

NCT07046494

Conditions

Bipolar 1 Disorder

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

RAP-219

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-10. This information was provided to ClinicalTrials.gov by Rapport Therapeutics Inc. on 2025-11-24.